Merck & Co Inc said on Monday its experimental therapy helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study, lifting its shares about 4%.
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid//said on Monday its experimental therapy helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study, lifting its shares about 4%.
Sotatercept, combined with a background therapy, helped patients with pulmonary arterial hypertension to walk about 40.8 meters more in six minutes.of Acceleron Pharma in 2021, also showed significant improvement in eight of the nine secondary goals, including reducing the risk of death or clinical worsening of condition by 84% compared to placebo.
J.P. Morgan analyst Chris Schott said the data exceeded the brokerage's expectations and "should confirm the drug as go-to add-on therapy" for pulmonary arterial hypertension., Merck said sotatercept had met the main goal of a late-stage study, but did not release the full data. Merck has been beefing up its portfolio of cardiovascular drugs as part of its strategy to counter a possible hit to sales to its best-selling drug Keytruda from biosimilar drugs in the next few years.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Carmel Clay adjusts school calendar for total solar eclipse in 2024As Central Indiana prepares for the area's first visible total solar eclipse in nearly 820 years, the Carmel Clay School Board has moved to change next year's spring break in light of the phenomenon.
Les mer »
MO Stock Price | Altria Group Inc. Stock Quote (U.S.: NYSE) | MarketWatchMO | Complete Altria Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Les mer »
BioMarin’s stock falls after another company’s dwarfism drug moves into Phase 3 clinical trialsShares of BioMarin Pharmaceutical Inc. were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. shared positive Phase 2 clinical data...
Les mer »
Proxy advisors urge shareholders to reject Ritchie Bros bid for IAAProxy advisory firms Institutional Shareholder Services and Glass Lewis on Monday recommended that shareholders reject Ritchie Brothers Auctioneers Inc's planned $7 billion acquisition of U.S. auto retailer IAA Inc .
Les mer »
Here are Monday's biggest analyst calls of the day: Apple, Tesla, Nio, Ferrari, Merck, Nvidia & moreHere are the biggest calls on Wall Street on Monday.
Les mer »
Some Pixel owners can't wait until MondayIf the March Pixel Feature Drop arrives on Monday as expected, those subscribed to the beta program will be able to exit the beta without a penalty.
Les mer »